title: Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment.
abstract: Anti-angiogenic therapy by blocking VEGF signalling combined with standard chemotherapy is a novel strategy for clinical cancer treatment. The mechanisms for enhanced antitumoral effects are still a matter of controversial debate. Tumor vessel "normalization" upon anti-angiogenic therapy leading to improved drug delivery has been proposed as possible mechanism. Therefore, aim of the study was to investigate tumor microvascular function upon anti-VEGFR treatment in highly vascularized melanomas. A detailed intravital-microscopic analysis of tumor microcirculation including the distribution pattern of vessel diameters and blood flow velocities was performed in melanomas grown in dorsal skinfold chambers of hamsters. Animals with highly vascularized established tumors were treated by a VEGFR tyrosin kinase inhibitor (SU5416) on 3 repetitive days. Tumor tissue oxygenation was measured by phosphorescence quenching technique. Overall tumor microcirculation of subcutaneous tumors was investigated by contrast enhanced MRI (CE-MRI). Vessel density was significantly decreased in treated animals. A significant shift in the distribution patterns towards increased vessel diameters and faster red blood cell velocities in remaining tumor vessels was observed upon anti-VEGF treatment, compensating reduced vascular density. Moreover, a trend towards elevated pO(2) levels in treated tumors was observed. Compared to controls, inflow kinetics of tumors quantified by CE-MRI as well as overall uptake of contrast agent in tumor tissue were significantly increased following short-term SU5416 treatment. In conclusion the results confirm temporarily improved tumor microvascular function in highly vascularized melanomas upon short term anti-VEGFR treatment leading to enhanced tumor blood supply and oxygenation potentially improving the efficacy of simultaneous chemo- or radiotherapy.
authors.affiliation: Department of Surgery, Klinikum Grosshadern, University of Munich (LMU), Germany. martin.eichhorn@med.uni-muenchen.de
authors.forename: M E
authors.initials: ME
authors.lastname: Eichhorn
authors.forename: S
authors.initials: S
authors.lastname: Strieth
authors.forename: S
authors.initials: S
authors.lastname: Luedemann
authors.forename: A
authors.initials: A
authors.lastname: Kleespies
authors.forename: U
authors.initials: U
authors.lastname: Nöth
authors.forename: A
authors.initials: A
authors.lastname: Passon
authors.forename: G
authors.initials: G
authors.lastname: Brix
authors.forename: K W
authors.initials: KW
authors.lastname: Jauch
authors.forename: C J
authors.initials: CJ
authors.lastname: Bruns
authors.forename: M
authors.initials: M
authors.lastname: Dellian
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D045744:Cell Line, Tumor; D006224:Cricetinae; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008545:Melanoma / Q000098:blood supply* / Q000473:pathology*; D008647:Mesocricetus; D008833:Microcirculation; D008853:Microscopy / Q000379:methods*; D008856:Microscopy, Fluorescence / Q000379:methods*; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000098:blood supply*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors* / Q000737:chemistry
chemical_list: D020533:Angiogenesis Inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor